Form 13-F position report

IGM BIOSCIENCES INC COM

Reported by Nuveen Asset Management LLC

IGMS CUSIP 449585108 Manager CIK 0001521019

Reported 39,607 shares, up 6,747 (20.5%) from the prior quarter.

Reported value 30.8%; share count 20.5% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2021
Shares 39,607 Quarter-end amount reported
Reported value $3,295,000 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2020-03-31 1078000
2020-06-30 3982000
2020-09-30 3828000
2020-12-31 2616000
2021-03-31 2520000
2021-06-30 3295000
2021-09-30 2035000
2021-12-31 700000
2022-03-31 420000
2022-06-30 1581000
2022-09-30 1027000
2022-12-31 1414000
2023-03-31 1115000
2023-06-30 730896
2023-09-30 661211
2023-12-31 414028
2024-03-31 393228
2024-06-30 279946
2024-09-30 744548
2024-12-31 275042

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for IGM BIOSCIENCES INC COM held by Nuveen Asset Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Unchanged 45,015 0 (0.0%) < 0.01% $275,042 2025-02-14
Q3 2024 Added 45,015 +4,266 (10.5%) < 0.01% $744,548 2024-11-14
Q2 2024 Unchanged 40,749 0 (0.0%) < 0.01% $279,946 2024-08-09
Q1 2024 Reduced 40,749 -9,074 (-18.2%) < 0.01% $393,228 2024-05-13
Q4 2023 Reduced 49,823 -29,364 (-37.1%) < 0.01% $414,028 2024-02-14
Q3 2023 Unchanged 79,187 0 (0.0%) < 0.01% $661,211 2023-11-14
Q2 2023 Reduced 79,187 -1,982 (-2.4%) < 0.01% $730,896 2023-08-14
Q1 2023 Reduced 81,169 -1,935 (-2.3%) < 0.01% $1,115,000 2023-05-15
Q4 2022 Added 83,104 +37,920 (83.9%) < 0.01% $1,414,000 2023-02-14
Q3 2022 Reduced 45,184 -42,505 (-48.5%) < 0.01% $1,027,000 2022-11-14
Q2 2022 Added 87,689 +61,277 (232.0%) < 0.01% $1,581,000 2022-08-15
Q1 2022 Added 26,412 +2,530 (10.6%) < 0.01% $420,000 2022-05-16
Q4 2021 Reduced 23,882 -7,074 (-22.9%) < 0.01% $700,000 2022-02-14
Q3 2021 Reduced 30,956 -8,651 (-21.8%) < 0.01% $2,035,000 2021-11-12
Q2 2021 Added 39,607 +6,747 (20.5%) < 0.01% $3,295,000 2021-08-16
Q1 2021 Added 32,860 +3,230 (10.9%) < 0.01% $2,520,000 2021-05-17
Q4 2020 Reduced 29,630 -22,223 (-42.9%) < 0.01% $2,616,000 2021-02-16
Q3 2020 Reduced 51,853 -2,693 (-4.9%) < 0.01% $3,828,000 2020-11-16
Q2 2020 Added 54,546 +35,350 (184.2%) < 0.01% $3,982,000 2020-08-14
Q1 2020 Added 19,196 +11,378 (145.5%) < 0.01% $1,078,000 2020-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

128 managers reported IGM BIOSCIENCES INC COM for Q2 2021.

Managers reporting IGM BIOSCIENCES INC COM in Q2 2021.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Redmile Group LLC Unchanged 3,425,455 0 4.22% $284,998,000 8 qtrs
BAKER BROS ADVISORS LP Unchanged 3,156,102 0 1.15% $262,588,000 8 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 1,986,071 +189,760 0.02% $165,241,000 8 qtrs
Artal Group S A Reduced 1,100,000 -25,000 1.86% $91,520,000 4 qtrs
ALKEON CAPITAL MANAGEMENT LLC Reduced 1,051,429 -2,123 0.13% $87,479,000 6 qtrs
Woodline Partners LP Added 745,393 +314,710 1.16% $62,017,000 4 qtrs
BlackRock Inc Reduced 632,801 -106,244 < 0.01% $52,650,000 8 qtrs
STATE STREET CORPORATION Reduced 586,838 -100,377 < 0.01% $48,825,000 7 qtrs
PICTET ASSET MANAGEMENT LTD Added 439,297 +70,034 0.04% $36,550,000 6 qtrs
The Goldman Sachs Group Inc Reduced 422,883 -317,427 < 0.01% $35,184,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2021
Filed
August 16, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
39,607
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.